{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:31:57Z","timestamp":1780414317215,"version":"3.54.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T00:00:00Z","timestamp":1693180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T00:00:00Z","timestamp":1693180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s40262-023-01292-w","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T05:01:40Z","timestamp":1693198900000},"page":"1509-1522","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacokinetics and Pharmacodynamics of Patisiran in Patients with hATTR Amyloidosis and with Polyneuropathy After Liver Transplantation"],"prefix":"10.1007","volume":"62","clinical-trial-number":[{"clinical-trial-number":"nct03862807","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1248-616X","authenticated-orcid":false,"given":"Prajakta","family":"Badri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahru","family":"Habtemariam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Melch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie A.","family":"Clausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Arum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Y.","family":"Jay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Vest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel J.","family":"Robbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,28]]},"reference":[{"issue":"21","key":"1292_CR1","doi-asserted-by":"publisher","first-page":"11793","DOI":"10.1016\/S0021-9258(17)39100-7","volume":"260","author":"DR Soprano","year":"1985","unstructured":"Soprano DR, Herbert J, Soprano KJ, Schon EA, Goodman DS. Demonstration of transthyretin mRNA in the brain and other extrahepatic tissues in the rat. J Biol Chem. 1985;260(21):11793\u20138.","journal-title":"J Biol Chem"},{"issue":"3","key":"1292_CR2","first-page":"497","volume":"31","author":"T Cavallaro","year":"1990","unstructured":"Cavallaro T, Martone RL, Dwork AJ, Schon EA, Herbert J. The retinal pigment epithelium is the unique site of transthyretin synthesis in the rat eye. Invest Ophthalmol Vis Sci. 1990;31(3):497\u2013501.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"1292_CR3","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.1399-0004.1991.tb03085.x","volume":"40","author":"G Holmgren","year":"1991","unstructured":"Holmgren G, Steen L, Ekstedt J, Groth CG, Ericzon BG, Eriksson S, et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet. 1991;40(3):242\u20136.","journal-title":"Clin Genet"},{"issue":"5213","key":"1292_CR4","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.7754382","volume":"268","author":"HL Monaco","year":"1995","unstructured":"Monaco HL, Rizzi M, Coda A. Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. Science. 1995;268(5213):1039\u201341.","journal-title":"Science"},{"issue":"3","key":"1292_CR5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/jcpt.12145","volume":"39","author":"Y Sekijima","year":"2014","unstructured":"Sekijima Y. Recent progress in the understanding and treatment of transthyretin amyloidosis. J Clin Pharm Ther. 2014;39(3):225\u201333.","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"1292_CR6","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1006\/bbrc.2000.3203","volume":"274","author":"M Yazaki","year":"2000","unstructured":"Yazaki M, Tokuda T, Nakamura A, Higashikata T, Koyama J, Higuchi K, et al. Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin. Biochem Biophys Res Commun. 2000;274(3):702\u20136.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"1292_CR7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/ncpneph0169","volume":"2","author":"JD Gillmore","year":"2006","unstructured":"Gillmore JD, Hawkins PN. Drug Insight: emerging therapies for amyloidosis. Nat Clin Pract Nephrol. 2006;2(5):263\u201370.","journal-title":"Nat Clin Pract Nephrol"},{"issue":"5","key":"1292_CR8","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/mus.26034","volume":"57","author":"HH Schmidt","year":"2018","unstructured":"Schmidt HH, Waddington-Cruz M, Botteman MF, Carter JA, Chopra AS, Hopps M, et al. Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve. 2018;57(5):829\u201337.","journal-title":"Muscle Nerve"},{"issue":"8","key":"1292_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1750-1172-8-31","volume":"20","author":"Y Ando","year":"2013","unstructured":"Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;20(8):31.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1292_CR10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1080\/13506120410001682569","volume":"11","author":"LH Connors","year":"2004","unstructured":"Connors LH, Yamashita T, Yazaki M, Skinner M, Benson MD. A rare transthyretin mutation (Asp18Glu) associated with cardiomyopathy. Amyloid. 2004;11(1):61\u20136.","journal-title":"Amyloid"},{"issue":"4","key":"1292_CR11","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/mus.20821","volume":"36","author":"MD Benson","year":"2007","unstructured":"Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve. 2007;36(4):411\u201323.","journal-title":"Muscle Nerve"},{"issue":"12","key":"1292_CR12","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S1474-4422(11)70246-0","volume":"10","author":"V Plante-Bordeneuve","year":"2011","unstructured":"Plante-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011;10(12):1086\u201397.","journal-title":"Lancet Neurol"},{"key":"1292_CR13","doi-asserted-by":"publisher","unstructured":"Olofsson BO, Backman C, Karp K, Suhr OB. Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type. Transplantation. 2002;73(5):745\u201351. https:\/\/doi.org\/10.1097\/00007890-200203150-00015.","DOI":"10.1097\/00007890-200203150-00015"},{"issue":"11","key":"1292_CR14","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1111\/j.1600-6143.2007.01969.x","volume":"7","author":"S Yamamoto","year":"2007","unstructured":"Yamamoto S. Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single- center experience over 16 years. Am J Transplant. 2007;7(11):2597\u2013604.","journal-title":"Am J Transplant"},{"issue":"4","key":"1292_CR15","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1212\/WNL.0b013e3181ea15d4","volume":"75","author":"L Jj","year":"2010","unstructured":"Jj L. Progression of transthyre-tin amyloid neuropathy after liver transplantation. Neurology. 2010;75(4):324\u20137.","journal-title":"Neurology"},{"issue":"3","key":"1292_CR16","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1006\/bbrc.2000.3203","volume":"274","author":"M Yazaki","year":"2000","unstructured":"Yazaki M. Cardiac amyloid in pa-tients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin. Biochem Biophys Res Commun. 2000;274(3):702\u20136.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"1292_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2013.66","volume":"17","author":"BL Mui","year":"2013","unstructured":"Mui BL, Tam YK, Jayaraman M, Ansell SM, Du X, Tam YY, et al. Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles. Mol Ther Nucleic Acids. 2013;17(2): e139.","journal-title":"Mol Ther Nucleic Acids."},{"issue":"7","key":"1292_CR18","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/mt.2010.85","volume":"18","author":"A Akinc","year":"2010","unstructured":"Akinc A, Querbes W, De S, Qin J, Frank-Kamenetsky M, Jayaprakash KN, et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther. 2010;18(7):1357\u201364.","journal-title":"Mol Ther"},{"issue":"7","key":"1292_CR19","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","volume":"25","author":"PR Cullis","year":"2017","unstructured":"Cullis PR, Hope MJ. Lipid nanoparticle systems for enabling gene therapies. Mol Ther. 2017;25(7):1467\u201375.","journal-title":"Mol Ther"},{"issue":"34","key":"1292_CR20","doi-asserted-by":"publisher","first-page":"8529","DOI":"10.1002\/anie.201203263","volume":"51","author":"M Jayaraman","year":"2012","unstructured":"Jayaraman M, Ansell SM, Mui BL, Tam YK, Chen J, Du X, et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl. 2012;51(34):8529\u201333.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"2","key":"1292_CR21","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nbt.1602","volume":"28","author":"SC Semple","year":"2010","unstructured":"Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, Cho CK, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 2010;28(2):172\u20136.","journal-title":"Nat Biotechnol"},{"issue":"15","key":"1292_CR22","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1038\/sj.gt.3301506","volume":"8","author":"IM Hafez","year":"2001","unstructured":"Hafez IM, Maurer N, Cullis PR. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther. 2001;8(15):1188\u201396.","journal-title":"Gene Ther"},{"issue":"1","key":"1292_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018;379(1):11\u201321.","journal-title":"N Engl J Med"},{"issue":"1","key":"1292_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S1474-4422(20)30368-9","volume":"20","author":"D Adams","year":"2021","unstructured":"Adams D, Polydefkis M, Gonzalez-Duarte A, Wixner J, Kristen AV, Schmidt HH, et al. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurol. 2021;20(1):49\u201359.","journal-title":"Lancet Neurol"},{"key":"1292_CR25","unstructured":"Onpattro (Patisiran) lipid complex injection, for intravenous use [prescribing information]. Cambridge: Alnylam Pharmaceuticals, Inc. 2018."},{"key":"1292_CR26","unstructured":"European Medicines Agency. Summary of product characteristics: Onpattro 2 mg\/mL concentrate for solution for infusion. 2018."},{"key":"1292_CR27","unstructured":"Alnylam Pharmaceuticals Inc. Alnylam announces approval in Japan of ONPATTRO\u00ae for the treatment of hereditary ATTR amyloidosis with polyneuropathy. 2019. https:\/\/investors.alnylam.com\/press-release?id=23886. Accessed 7 Aug 2023."},{"key":"1292_CR28","unstructured":"CADTH. Patisiran. 2019. https:\/\/www.cadth.ca\/patisiran. Accessed 21 June 2023."},{"key":"1292_CR29","unstructured":"Swissmedic. Abbreviated information for health care professionals for ONPATTRO 10 mg\/5 ml, concentrate for solution for infusion (version September 2019). 2019. https:\/\/www.swissmedicinfo.ch. Accessed 9 Mar 2021."},{"key":"1292_CR30","unstructured":"Alnylam Pharmaceuticals Inc. Alnylam announces approval in Brazil of ONPATTRO\u00ae for the treatment of hereditary ATTR amyloidosis with polyneuropathy. 2020. https:\/\/investors.alnylam.com\/press-release?id=24606. Accessed 9 Mar 2021."},{"issue":"5","key":"1292_CR31","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/00019052-200410000-00012","volume":"17","author":"AHP Stangou","year":"2004","unstructured":"Stangou AHP. Liver transplantation in transthyretin-related familial amyloid polyneuropathy. Curr Opin Neurol. 2004;17(5):615\u201320.","journal-title":"Curr Opin Neurol"},{"issue":"4","key":"1292_CR32","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/13506129.2018.1550061","volume":"25","author":"V Algalarrondo","year":"2018","unstructured":"Algalarrondo V, Antonini T, Theaudin M, Chemla D, Benmalek A, Castaing D, et al. Cause of death analysis and temporal trends in survival after liver transplantation for transthyretin familial amyloid polyneuropathy. Amyloid. 2018;25(4):253\u201360.","journal-title":"Amyloid"},{"key":"1292_CR33","unstructured":"FAPWTR Results from the Familial World Transplant Registry. http:\/\/www.FAPWTR.org. Published 2018. Accessed 21 June 2023."},{"issue":"11","key":"1292_CR34","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1111\/j.1600-6143.2007.01969.x","volume":"7","author":"S Yamamoto","year":"2007","unstructured":"Yamamoto S, Wilczek HE, Nowak G, Larsson M, Oksanen A, Iwata T, et al. Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years. Am J Transplant. 2007;7(11):2597\u2013604.","journal-title":"Am J Transplant"},{"key":"1292_CR35","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1111\/ajt.17009","volume":"22","author":"HH Schmidt","year":"2022","unstructured":"Schmidt HH, Wixner J, Plant\u00e9-Bordeneuve V, Mu\u00f1oz-Beamud F, Llad\u00f3 L, Gillmore JD, et al. Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation. Am J Transplant. 2022;22(6):1646\u201357. https:\/\/doi.org\/10.1111\/ajt.17009.","journal-title":"Am J Transplant"},{"key":"1292_CR36","unstructured":"European Medicines Agency. Assessment report: onpattro (patisiran) 2018. https:\/\/www.ema.europa.eu\/documents\/assessment-report\/onpattro-epar-public-assessment-report_.pdf. Accessed 9 Mar 2021."},{"issue":"1","key":"1292_CR37","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/jcph.1480","volume":"60","author":"X Zhang","year":"2020","unstructured":"Zhang X, Goel V, Attarwala H, Sweetser MT, Clausen VA, Robbie GJ. Patisiran pharmacokinetics, pharmacodynamics, and exposure-response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin-mediated (hATTR) amyloidosis. J Clin Pharmacol. 2020;60(1):37\u201349.","journal-title":"J Clin Pharmacol"},{"key":"1292_CR38","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/jcph.1553","volume":"60","author":"X Zhang","year":"2020","unstructured":"Zhang X, Goel V, Robbie GJ. Pharmacokinetics of patisiran, the first approved RNA interference therapy in patients with hereditary transthyretin-mediated amyloidosis. J Clin Pharmacol. 2020;60(5):573\u201385.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1292_CR39","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22\u201331.","journal-title":"N Engl J Med"},{"issue":"24","key":"1292_CR40","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1001\/jama.2023.4570","volume":"329","author":"A Khvorova","year":"2023","unstructured":"Khvorova A. siRNAs-a new class of medicines. JAMA. 2023;329(24):2185\u20136.","journal-title":"JAMA"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01292-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-023-01292-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01292-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T08:30:12Z","timestamp":1695630612000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-023-01292-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,28]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1292"],"URL":"https:\/\/doi.org\/10.1007\/s40262-023-01292-w","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,28]]},"assertion":[{"value":"24 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by Alnylam Pharmaceuticals Inc. Alnylam Pharmaceuticals Inc. contributed to the study design, research, and interpretation of data, and the writing, reviewing, and approving of the manuscript for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Prajakta Badri,\u00a0Bahru Habtemariam, Megan Melch, Valerie A. Clausen,\u00a0Seth Arum, Xingyu Li, Patrick Y. Jay, John Vest, Gabriel J. Robbie are or were Alnylam Pharmaceutical employees and may hold Alnylam stocks or options.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This study was conducted in accordance with the Good Clinical Practice Guideline as defined by the International Conference on Harmonisation, the Declaration of Helsinki, and all applicable federal and local regulations. The study was approved by independent institutional review boards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"PB, MM and XL contributed to the data analyses for this manuscript, interpretation of results, writing and reviewing of the manuscript. BH, VC,\u00a0SA, PJ, JV and GR contributed to the study design, interpretation of results, and writing and reviewing of the manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Written informed consent was obtained from each subject before any study- related procedures were performed.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"The study protocol was approved by central and local institutional review boards and ethics committees. The study was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided written informed consent prior.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors provide consent to publish these data.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Anonymized individual participant data that support these results would be made available in a secure-access environment 12 months after study completion and when the product and indication have been approved for no less than 12 months in the USA and\/or the EU. Access will be provided contingent upon the approval of a research proposal and the execution of a data sharing agreement. Requests for access to data can be submitted via the website .","order":11,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}}]}}